S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
The "King Of Quants" sees 10X potential... (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
3 Secrets To Consistent Trading Success (Ad)pixel
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
3 Secrets To Consistent Trading Success (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
The "King Of Quants" sees 10X potential... (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
3 Secrets To Consistent Trading Success (Ad)pixel
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
3 Secrets To Consistent Trading Success (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
The "King Of Quants" sees 10X potential... (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
3 Secrets To Consistent Trading Success (Ad)pixel
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
3 Secrets To Consistent Trading Success (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
The "King Of Quants" sees 10X potential... (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
3 Secrets To Consistent Trading Success (Ad)pixel
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
3 Secrets To Consistent Trading Success (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
NASDAQ:GLUE

Monte Rosa Therapeutics - GLUE Stock Forecast, Price & News

$6.94
-0.28 (-3.88%)
(As of 03/20/2023 12:00 AM ET)
Add
Compare
Today's Range
$6.86
$7.42
50-Day Range
$5.95
$8.21
52-Week Range
$5.74
$15.52
Volume
78,225 shs
Average Volume
143,419 shs
Market Capitalization
$335.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.40

Monte Rosa Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
165.1% Upside
$18.40 Price Target
Short Interest
Bearish
5.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Monte Rosa Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.82) to ($2.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

539th out of 988 stocks

Biological Products, Except Diagnostic Industry

97th out of 162 stocks


GLUE stock logo

About Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Receive GLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GLUE Stock News Headlines

Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
GLUE Monte Rosa Therapeutics, Inc.
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Monte Rosa Therapeutics: Q2 Earnings Snapshot
Monte Rosa Therapeutics, Inc. (GLUE)
See More Headlines
Receive GLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GLUE Company Calendar

Last Earnings
3/29/2022
Today
3/20/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLUE
Fax
N/A
Employees
93
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.40
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+165.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-73,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.47 per share

Miscellaneous

Free Float
46,705,000
Market Cap
$335.89 million
Optionable
Not Optionable
Beta
0.96

Key Executives

  • Dr. Markus Warmuth M.D. (Age 51)
    Pres, CEO & Director
    Comp: $842.99k
  • Dr. Owen B. Wallace Ph.D. (Age 53)
    Chief Scientific Officer
    Comp: $578.36k
  • Dr. Filip Janku M.D. (Age 47)
    Ph.D., Chief Medical Officer
    Comp: $511.55k
  • Mr. Ajim A. Tamboli C.F.A. (Age 45)
    Chief Financial Officer
  • Ms. Jennifer Champoux
    Sr. VP of Operations
  • Dr. Sharon Townson Ph.D. (Age 47)
    Chief Technology Officer
  • Mr. Phil Nickson J.D. (Age 43)
    Ph.D., Gen. Counsel
  • Dr. John C. Castle Ph.D. (Age 51)
    Chief Data Scientist
  • Dr. Jullian G. Jones J.D. (Age 46)
    M.B.A., Ph.D., Chief Bus. Officer
  • Dr. Silvia Buonamici Ph.D.
    Sr. VP of Drug Discovery Biology













GLUE Stock - Frequently Asked Questions

Should I buy or sell Monte Rosa Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GLUE shares.
View GLUE analyst ratings
or view top-rated stocks.

What is Monte Rosa Therapeutics' stock price forecast for 2023?

4 equities research analysts have issued twelve-month price targets for Monte Rosa Therapeutics' stock. Their GLUE share price forecasts range from $11.00 to $22.00. On average, they predict the company's stock price to reach $18.40 in the next twelve months. This suggests a possible upside of 165.1% from the stock's current price.
View analysts price targets for GLUE
or view top-rated stocks among Wall Street analysts.

How have GLUE shares performed in 2023?

Monte Rosa Therapeutics' stock was trading at $7.61 at the beginning of the year. Since then, GLUE stock has decreased by 8.8% and is now trading at $6.94.
View the best growth stocks for 2023 here
.

Are investors shorting Monte Rosa Therapeutics?

Monte Rosa Therapeutics saw a drop in short interest in February. As of February 28th, there was short interest totaling 2,290,000 shares, a drop of 8.0% from the February 13th total of 2,490,000 shares. Based on an average daily volume of 145,000 shares, the days-to-cover ratio is presently 15.8 days. Currently, 5.9% of the company's stock are short sold.
View Monte Rosa Therapeutics' Short Interest
.

When is Monte Rosa Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our GLUE earnings forecast
.

How were Monte Rosa Therapeutics' earnings last quarter?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) issued its quarterly earnings results on Tuesday, March, 29th. The company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.43.

What ETFs hold Monte Rosa Therapeutics' stock?

ETFs with the largest weight of Monte Rosa Therapeutics (NASDAQ:GLUE) stock in their portfolio include BlackRock Future Health ETF (BMED).Fidelity Growth Opportunities ETF (FGRO).

When did Monte Rosa Therapeutics IPO?

(GLUE) raised $211 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 11,700,000 shares at a price of $17.00-$19.00 per share.

What is Monte Rosa Therapeutics' stock symbol?

Monte Rosa Therapeutics trades on the NASDAQ under the ticker symbol "GLUE."

Who are Monte Rosa Therapeutics' major shareholders?

Monte Rosa Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include NEA Management Company LLC (15.89%), Avoro Capital Advisors LLC (8.94%), Price T Rowe Associates Inc. MD (7.61%), T. Rowe Price Investment Management Inc. (4.00%), Geode Capital Management LLC (1.16%) and Millennium Management LLC (0.81%). Insiders that own company stock include Cormorant Asset Management, Lp and Versant Venture Capital Vi, L.

How do I buy shares of Monte Rosa Therapeutics?

Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Monte Rosa Therapeutics' stock price today?

One share of GLUE stock can currently be purchased for approximately $6.94.

How much money does Monte Rosa Therapeutics make?

Monte Rosa Therapeutics (NASDAQ:GLUE) has a market capitalization of $335.89 million. The company earns $-73,960,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.

How can I contact Monte Rosa Therapeutics?

The official website for the company is www.monterosatx.com. The company can be reached via phone at 617-949-2643 or via email at ir@monterosatx.com.

This page (NASDAQ:GLUE) was last updated on 3/21/2023 by MarketBeat.com Staff